Breast Cancer | Disease Landscape & Forecast | G7 | 2024
CDK4/6 inhibitors (Pfizer’s Ibrance, Novartis’s Kisqali, and Eli Lilly’s Verzenio/Verzenios) combined with endocrine therapy are central to the treatment of metastatic hormone receptor-positive / HER2-negative breast cancer and are expected to drive robust sales in the early-stage setting as well. Novel biomarker-driven therapies (i.e., Novartis’s Piqray, AstraZeneca’s Truqap, and Menarini’s Orserdu) gained approval recently, and the market is set to become increasingly crowded with agents that seek to overcome endocrine resistance. The treatment of HER2-positive breast cancer is rapidly evolving owing to the approval and forecast label expansions of agents such as Enhertu (Daiichi Sankyo / AstraZeneca), which has become a key therapy for the newly defined HER2-low subgroup. In triple-negative breast cancer, the use of immune checkpoint inhibitors (Merck & Co.’s Keytruda) is standard, and TROP2-targeted agents (Gilead’s Trodelvy)—currently used in the pretreated metastatic setting—are expected to move to the more-lucrative earlier lines of treatment.
Questions answered
- How large are the clinically and commercially relevant drug-treatable breast cancer populations?
- What is the expected market impact of recent drug approvals, such as Piqray, Orserdu, Truqap, and Enhertu, on the various subpopulations of breast cancer?
- Which are the most promising agents in the pipeline, and how will they shape the future of this therapy market?
- What key drivers and constraints will affect the breast cancer therapy market over the forecast period?
Geography: United States, EU5, Japan
Primary research: 19 country-specific interviews with thought-leading medical oncologists and supported by survey data collected for this and other Clarivate research
Epidemiology: Incidence of breast cancer by country; drug-treatable / drug-treated cases segmented by hormone receptor and HER2 status, stage, menopausal status, and line of therapy
Forecast: 10-year, annualized, drug-level sales and patient share of key breast cancer therapies through 2033, segmented by brands and epidemiological subpopulations
Drug treatments: Coverage of select current and emerging therapies
Product description
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research.
Key features
Disease Landscape & Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.
Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.
